Press Release – New York, NY – November 26, 2025 – Sichenzia Ross Ference Carmel LLP announced that it represented LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a biotech company focused on advancing cancer treatments, in its acquisition of Liora Technologies Europe Ltd., a UK-based company pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora Technologies will become a wholly owned subsidiary of LIXTE Biotechnology.
The SRFC team congratulates LIXTE Biotechnology’s CEO, Geordan Pursglove, on the completion of the acquisition.
The SRFC team was led by partners Ross Carmel and Carl Kleidman, with associate Yini Lai.